Sonoma Pharmaceuticals Announces FDA Approval of Expanded Indication for Alevicyn™ to Add Antimicrobial Language
November 16 2017 - 7:45AM
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care, today announced that the U.S.
Food and Drug Administration (FDA) has approved an expanded claim
for the company’s signature dermatology product, Alevicyn™ Dermal
Spray, to include antimicrobial language and antimicrobial data
against clinically relevant microorganisms.
“This important FDA milestone further validates Alevicyn’s
antimicrobial activity against clinically relevant microorganisms
and provides additional on-label evidence of patient benefits,”
said Jeff Day, president of Sonoma Pharmaceutical’s dermatology
division. “These new claims differentiate Alevicyn from
topical steroids and should help propel our sales growth even
faster as a strong alternative to those older products.”
Alevicyn (www.alevicyn.com) products, available via
prescription, provide dermatologists with a safe and clinically
proven approach to management of atopic dermatitis without the side
effects of topical steroids and resistance issues associated with
the overuse of antibiotics. In addition, the Alevicyn products
are used during and post-treatment on skin cancer surgical
procedures. Over the last three years, there have been over
61,000 prescriptions filled for the Alevicyn family of products,
valued at over $7.5 million. For more information regarding
Alevicyn visit www.alevicyn.com.
About the Global Dermatology MarketAccording to
BCC Research, skin conditions are among the most common health
problems in most national populations, collectively exceeding the
prevalence of conditions such as obesity, hypertension and cancer.
The considerable costs of skin diseases include physician visits,
hospital care, prescription drugs and over-the-counter products for
treating or managing these conditions, as well as indirect costs
due to productivity losses.
The global market for skin disease treatment technologies is
estimated to reach $20.4 billion in 2020. The U.S market is the
largest segment and should reach $8.6 billion in 2020. The
BRIC (Brazil, Russia, India, China) countries are the fastest
growing region of the global dermatology market and should total
more than $4.6 billion by 2020.
About Sonoma Pharmaceuticals, Inc.Sonoma is a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “believe,”
“achieve,” and “strive,” among others. Forward-looking statements
in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies,
as well as uncertainties relative to varying product formulations
and a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission. The Company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals®, Alevicyn™ and Microcyn® Technology are
trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc.
All other trademarks and service marks are the property of their
respective owners.
Media and Investor
Contact:
Sonoma Pharmaceuticals,
Inc.Dan McFaddenVP of Public and Investor
Relations(425) 753-2105dmcfadden@Sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Apr 2023 to Apr 2024